ABSTRACT
Palivizumab is currently recommended to high-risk children as a prophylaxis for respiratory syncytial virus (RSV) infection. However, it is still very expensive for developing countries like Brazil. Herein, we describe our strategy to minimize wastage of Palivizumab during the 2008 RSV season. Appointments were fixed for 304 children on 2 days of the week, so that a mean of 19.9 children received Palivizumab per day. That allowed remaining volumes of Palivizumab vials to be pooled and used for other children on the same day within the 6 h period after opening a vial. That strategy saved 26.3% of vials, which represents USD $749,143.75.
Subject(s)
Antibodies, Monoclonal/therapeutic use , Antiviral Agents/therapeutic use , Respiratory Syncytial Virus Infections/drug therapy , Antibodies, Monoclonal, Humanized , Brazil , Female , Humans , Injections, Intramuscular , Male , Palivizumab , Respiratory Syncytial Virus Infections/prevention & control , Respiratory Syncytial Virus, Human , SeasonsABSTRACT
Com o objetivo de avaliar a eficácia da biópsia na elucidaçäo diagnóstica em adenomegalia em crianças, os autores estudaram 54 prontuários e 55 biópsias do Serviço de Anatomia-Patológica de dois hospitais situados na cidade de Santos. A análise mostrou, em 2/3 dos casos, Adenite Inespecífica (benigna). Foram identificados 10 casos de Tuberculose, 5 de Doença de Hodgkin e 1 de arranhadura de gato. O "índice terapêutico" (porcentagem de biópsias diagnósticas que possibilitam tratamento específico) foi de 35,2 (por cento), o que significa que a indicaçäo da biópsia foi correta e oportuna
